News

Filter

Current filters:

AmgenBiotechnology

1 to 9 of 219 results

Prime Therapeutics welcomes FDA's approval of first biosimilar in USA, but says more clarity is needed

Prime Therapeutics welcomes FDA's approval of first biosimilar in USA, but says more clarity is needed

09-03-2015

Prime Therapeutics, a non-profit US pharmacy benefit manager serving more than 26 million members, has…

AmgenBiosimilarsBiotechnologyNeupogenNovartisOncologyRegulationSandozUSAZarxio

Sandoz’s Zarxio first biosimilar to be approved under new FDA pathway

Sandoz’s Zarxio first biosimilar to be approved under new FDA pathway

06-03-2015

Sandoz, the generics unit of Swiss pharma giant Novartis, today received approval from the US Food and…

AmgenBiosimilarsBiotechnologyNeupogenNovartisOncologyRegulationSandozUSAZarxioZarzio

Amgen licenses AMG 714 to start-up Celimmune

Amgen licenses AMG 714 to start-up Celimmune

02-03-2015

USA-based biotech company Amgen has licensed a Phase II-stage anti-IL-15 monoclonal antibody, AMG 714,…

AmgenBiotechnologyGastro-intestinalsImmunologicalsLicensingUSA

Amgen's Kyprolis doubles progression-free survival in head-to-head against Velcade

Amgen's Kyprolis doubles progression-free survival in head-to-head against Velcade

02-03-2015

USA-based biotech firm Amgen and its subsidiary Onyx Pharmaceuticals have announced the interim results…

AmgenBiotechnologyKyprolisOncologyResearchUSAVelcade

Amgen’s 4th-qtr 2014 earnings and sales beat expectations

Amgen’s 4th-qtr 2014 earnings and sales beat expectations

28-01-2015

US biotech major Amgen reported financial results after markets closed yesterday, revealing that fourth-quarter…

AmgenBiotechnologyFinancialUSA

Sanofi and Regeneron’s Praluent BLA gains priority review from US FDA

26-01-2015

The US Food and Drug Administration has accepted for priority review the Biologics License Application…

alirocumabAmgenBiotechnologyCardio-vascularevolocumabPraluentRegeneron PharmaceuticalsRegulationSanofiUSA

Samsung Bioepis' Enbrel biosimilar candidate SB4 accepted for review by EMA

Samsung Bioepis' Enbrel biosimilar candidate SB4 accepted for review by EMA

21-01-2015

South Korea’s Samsung Bioepis says that the Marketing Authorization Application for its Enbrel (etanercept)…

AmgenAnti-Arthritics/RheumaticsBiogen IdecBiosimilarsBiotechnologyEnbrelEuropePfizerRegulationSamsung Bioepis

Amgen trials show no differences in quality of life between the FOLFOX regimens with or without Vectibix

Amgen trials show no differences in quality of life between the FOLFOX regimens with or without Vectibix

16-01-2015

USA-based Amgen, the world’s leading independent biotech firm, says that Phase II and Phase III studies…

AmgenBiotechnologyOncologyResearchVectibix

1 to 9 of 219 results

Back to top